$STOK insider trading
Over the last 12 months, Stoke Therapeutics insiders reported no purchases and 34 sales totaling $11.1M across SEC Form 4 filings. 74% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $11.1M 34 events
- Events · 12m
- 34 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 74% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,545 | $30.67 | $170K | -21.6% | plan · 2 tranches |
| Aug 18, 2026 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 4,767 | $32.03 | $153K | -15.7% | 2 tranches |
| Aug 18, 2026 | Kaye Edward M. MDD | ▼ Sale | 12,567 | $32.03 | $403K | -9.2% | 2 tranches |
| Aug 18, 2026 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 2,861 | $32.03 | $92K | -11.9% | 2 tranches |
| Aug 3, 2026 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 7,176 | $29.04 | $208K | -26% | plan · 2 tranches |
| Jul 1, 2026 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 7,228 | $32.66 | $236K | -20.8% | plan · 2 tranches |
| Jun 16, 2026 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 1,457 | $29.95 | $44K | -7.5% | plan |
| Jun 1, 2026 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 1,795 | $30.58 | $55K | -4.9% | plan |
| May 1, 2026 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 2,243 | $32.79 | $74K | -5.8% | plan |
| Apr 1, 2026 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 1,838 | $32.66 | $60K | -4.5% | plan |
| Mar 20, 2026 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 9,293 | $33.69 | $313K | -32.2% | plan · 2 tranches |
| Mar 19, 2026 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 14,311 | $31.92 | $457K | -26% | plan · 6 tranches |
| Mar 18, 2026 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 8,895 | $32.14 | $286K | -23.6% | 5 tranches |
| Mar 18, 2026 | Leggett ThomasChief Financial Officer · O | ▼ Sale | 4,578 | $32.14 | $147K | -31% | 5 tranches |
| Mar 18, 2026 | Hoitt JasonChief Patient Officer · O | ▼ Sale | 3,712 | $32.14 | $119K | -26.5% | 5 tranches |
| Mar 13, 2026 | LEVIN ARTHUR AD | ▼ Sale | 605 | $36.8 | $22K | -12.5% | plan |
| Mar 10, 2026 | Krainer Adrian R.D | ▼ Sale | 33,243 | $39.74 | $1.3M | -10.5% | plan |
| Mar 10, 2026 | TZIANABOS ARTHURInterim Executive Chair · O·D | ▼ Sale | 4,355 | $40 | $174K | -12.2% | plan |
| Mar 2, 2026 | Krainer Adrian R.D | ▼ Sale | 7,229 | $39.66 | $287K | -2.2% | plan |
| Dec 8, 2025 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 3,978 | $32.28 | $128K | -25.2% | plan · 2 tranches |
| Dec 8, 2025 | Kaye Edward M. MDD | ▼ Sale | 13,430 | $32.27 | $433K | -21.5% | plan · 3 tranches |
| Dec 5, 2025 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 9,803 | $31.25 | $306K | -38.3% | plan · 5 tranches |
| Dec 5, 2025 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,358 | $31.19 | $167K | -21.3% | plan · 4 tranches |
| Dec 5, 2025 | Kaye Edward M. MDD | ▼ Sale | 15,001 | $31.13 | $467K | -19.3% | plan · 5 tranches |
| Dec 3, 2025 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 4,576 | $30.22 | $138K | -18.9% | 4 tranches |
| Dec 3, 2025 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 4,020 | $30.22 | $121K | -21% | 4 tranches |
| Dec 3, 2025 | Kaye Edward M. MDD | ▼ Sale | 2,136 | $30.22 | $65K | -4% | 4 tranches |
| Nov 24, 2025 | Krainer Adrian R.D | ▼ Sale | 40,472 | $29.72 | $1.2M | -11.1% | plan |
| Nov 14, 2025 | Krainer Adrian R.D | ▼ Sale | 40,472 | $26.98 | $1.1M | -10% | plan · 2 tranches |
| Nov 3, 2025 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,931 | $25.72 | $153K | -45.2% | plan · 4 tranches |
| Oct 8, 2025 | Kaye Edward M. MDD | ▼ Sale | 25,000 | $30 | $750K | -33.7% | plan |
| Oct 3, 2025 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 10,000 | $25.06 | $251K | -45.8% | plan |
| Oct 3, 2025 | Kaye Edward M. MDD | ▼ Sale | 42,461 | $25.09 | $1.1M | -46.4% | plan |
| Oct 1, 2025 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,343 | $23.64 | $126K | -28.9% | plan |
| Sep 3, 2025 | Kaye Edward M. MDD | ▼ Sale | 61,885 | $20.13 | $1.2M | -40.3% | plan · 3 tranches |
| Sep 3, 2025 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 22,117 | $20.11 | $445K | -65.1% | plan · 3 tranches |
| Sep 2, 2025 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,501 | $19.87 | $109K | -22.9% | plan |
| Aug 18, 2025 | Ticho BarryCHIEF MEDICAL OFFICER · O | ▼ Sale | 2,805 | $18.24 | $51K | -10.5% | — |
| Aug 18, 2025 | Kaye Edward M. MDD | ▼ Sale | 12,126 | $18.24 | $221K | -7.3% | — |
| Aug 18, 2025 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 1,683 | $18.24 | $31K | -6.6% | — |
| Aug 13, 2025 | Allan JonathanGENERAL COUNSEL & CORP SEC · O | ▼ Sale | 13,712 | $15 | $206K | -41.1% | plan |
Every $STOK filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Stoke Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $STOK feed.